Today Reata Pharmaceuticals Inc - Class A (NASDAQ: RETA) is trading 10.70% higher.

The latest price, as of 12:07:00 est, was $25.02. Reata has climbed $2.42 over the previous day’s close.

157,772 shares have traded hands.

As of the previous close, Reata has a YTD change of 14.22%. The company expects its next earnings on 2022-08-08.

For technical charts, analysis, and more on Reata visit the company profile.

About Reata Pharmaceuticals Inc - Class A

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata's two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

To get more information on Reata Pharmaceuticals Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Reata Pharmaceuticals Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement

Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter

Another Crypto Winter Wipes Out Billions in Market Value

Inflation + Recession = Recipe for Volatility

Twitter Down 13% in Premarket Trading Friday as Musk Puts Deal on Hold

The Best Laid Plans of Mice and Men — Part I